Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in York. Study-provided care at no cost to qualified participants.
Access chronic lymphocytic leukemia specialists in York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic lymphocytic leukemia treatment provided free
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Sponsor: BeiGene
Check if you qualify for this chronic lymphocytic leukemia clinical trial in York, PA
If you're searching for chronic lymphocytic leukemia treatment options in York, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.